The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Abstract
Candida albicans and related species pathogenic for man become resistant to antifungal agents, in particular triazole compounds, by expression of efflux pumps that reduce drug accumulation, alteration of the structure or concentration of antifungal target proteins, and alteration of membrane sterol composition. The clinical consequences of antifungal resistance can be seen in treatment failures in patients and in changes in the prevalences of Candida species causing disease. These effects were seen unequivocally in HIV-infected patients with oropharyngeal candida infections, but their incidence has decreased dramatically with the introduction of highly active antiretroviral therapy. The evidence for similar emergence of antifungal-resistant yeast strains and species in other types of candida infections is confounded by non-standardised susceptibility testing methods and definitions of a resistant fungal isolate. Recent large-scale surveys of yeasts isolated from blood cultures, based on standardised methodology and resistance definitions, do not support the view that antifungal resistance in pathogenic yeasts constitutes a significant or growing therapeutic problem.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the factors that led to this development were the selection of intrinsically less susceptible organisms, such as C. glabrata and C. krusei, and the acquisition of resistance by previously susceptible strains of C. albicans following long-term azole exposure.”
In the citing paper
“In the early 1990s, increasing usage of fluconazole to treat human immunodeficiency virus (HIV)-infected persons with recurrent oropharyngeal candidiasis led to changes in the prevalence of different Candida species and to the emergence of azole-resistant strains (37).”
In the citing paper
“In the early 1990s, increasing use of fluconazole to treat HIV-infected patients with recurrent oropharyngeal candidiasis resulted in the selection of Candida species intrinsically less susceptible to azoles and in the emergence of azole drug-resistant strains in these patients due to the acquisition of resistance by previously susceptible strains of C. albicans (reviewed in reference 37).”
In the citing paper
“Our susceptibility results for Candida species other than C. albicans mirror those of a study by Kao et al. (16) and the results of other studies (25, 37) in showing a low level of in vitro azole resistance in C. glabrata and C. tropicalis, no resistance in C. parapsilosis or the newly reported C. dubliniensis, and the expected high level of resistance in C. krusei.”
In the citing paper
“Our susceptibility results for Candida species other than C. albicans mirror those of a study by Kao et al. (16) and the results of other studies (25, 37) in showing a low level of in vitro azole resistance in C. glabrata and C. tropicalis, no resistance in C. parapsilosis or the newly reported C. dubliniensis, and the expected high level of resistance in C. krusei.”
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citationSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
Self-citationSullivan, D. J., Haynes, K. A., Bennett, D. E., Coleman, D. C., & Westerneng, T. J. (1995) · Microbiology · doi:10.1099/13500872-141-7-1507 · Cited by 763
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758
The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S. (1997) · Clinical Infectious Diseases · doi:10.1086/513663 · Cited by 755
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Research works printed but not linked: 1
- Dellion, 1995, Diversity among yeasts isolated from patients with AIDS and oral candidosis: focus on fluconazole susceptibility testing results, J Mycol Med, 5, 98
Cited by
Antifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202
Self-citationDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., & Azeredo, J. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00278.x · Cited by 969
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
Metadata
- Authors
- Sanglard, D., & Odds, F. C.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- University of Aberdeen (GB)
- ORCID
- Sanglard, Dominique
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2002-02
- Volume
- 2
- Issue
- 2
- Pages
- 73-85
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2098169836
- Cited by
- 784
- References
- 115
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 11 · 2023: 23 · 2022: 20 · 2021: 17 · 2020: 25 · 2019: 25 · 2018: 31 · 2017: 47 · 2016: 29 · 2015: 40 · 2014: 58 · 2013: 43 · 2012: 41
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Update notices
- erratum (2002-08-01)
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, antifungal resistance, triazole resistance, efflux pumps, drug accumulation, HIV-associated candidiasis, oropharyngeal candidiasis, highly active antiretroviral therapy, bloodstream candidiasis, pathogenic yeasts
- MeSH terms
- Amphotericin B, Antifungal Agents, Azoles, Candida, Candidiasis, Cytochrome P-450 Enzyme System, Flucytosine, Humans, Microbial Sensitivity Tests, Oxidoreductases, Triazoles, Fungemia, Drug Resistance, Fungal, Sterol 14-Demethylase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. https://app.cochat.ai/papers/10.1016/s1473-3099(02)00181-0
- The paper
- Sanglard, D., & Odds, F. C. (2002). Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(02)00181-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.